Bibliography
1. Ahmadzadehfar H., Rahbar K., Kürpig S. et al. Early side effects and first results of radioligand therapy with 77Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study // EJNMMI Res. 2015; 5: 1.
2. Attard G., Parker C., Eeles R.A. Prostate cancer // Lancet. 2016; 387: 70-82.
3. Baum R.P., Kulkarni H.R., Schuchardt C. et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy // J. Nucl. Med. 2016; 57: 1006-13.
4. Beheshti M., Haim S., Zakavi R. et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: Influence of androgen deprivation therapy and correlation with PSA kinetics // J. Nucl. Med. 2013; 54: 833-40.
5. Benešová M., Schäfer M., Bauder-Wüst U. et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer // J. Nucl. Med. 2015; 56: 914-20.
6. Calabria F., Gallo G., Schillaci O. et al. Bio-distribution, imaging protocols and diagnostic accuracy of PET with tracers of lipogenesis in imaging prostate cancer: A comparison between 11C-choline, 18F-Fluoroethylcholine and 18F-methylcholine // Curr. Pharm. Des. 2015; 21: 4738-47.
7. Calabria F., Gangemi V., Gullà D. et al. 64Cu-PSMA uptake in meningioma: A potential pitfall of a promising radiotra–cer // Rev. Esp. Med. Nucl. Imagen. Mol. 2017; 36: 335-6.
8. Chakraborty P.S., Kumar R., Tripathi M. et al. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: A novel radiotracer for imaging of prostate carcinoma // Clin. Nucl. Med. 2015; 40: 328-9.
9. Cho S.Y., Szabo Z. Molecular imaging of urogenital di–seases // Semin. Nucl. Med. 2014; 44: 93-109.
10. Chondrogiannis S., Marzola M.C., Ferretti A. et al. Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? // Eur. J. Nucl. Med. Mol. Imaging. 2014; 41: 1293-300.
11. Chondrogiannis S., Marzola M.C., Grassetto G. et al. New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: Review of the literature about methodology and proposal of standardization // Biomed Res. Int. 2014; 2014: 215650-2. doi: 10.1155/2014/215650.
12. Cuccurullo V., Di Stasio G.D., Evangelista L. et al. Biochemical and pathophysiological premises to positron emission tomography with choline radiotracers // J. Cell. Physiol. 2017; 232: 270-5.
13. Cuccurullo V., Cascini G., Rossi A. et al. Pathophysiological premises to radiotracers for bone metastases // Q. J. Nucl. Med. Mol. Imaging. 2011; 55: 353-73.
14. Cuccurullo V., Di Stasio G.D., Mansi L. Nuclear medicine in prostate cancer: a new era for radiotracers // World J. of Nucl. Med. 2018; 17(2): 70-8.
15. De Marzo A.M., Nelson W.G., Isaacs W.B. et al. Pathological and molecular aspects of prostate cancer // Lancet. 2003; 361: 955-64.
16. Demirkol M.O., Acar Ö., Uçar B. et al. Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process // Prostate. 2015; 75: 748-57.
17. Evangelista L., Cervino A.R., Guttilla A. et al. 18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: Which is better? A literature revision // Nucl. Med. Biol. 2015; 42: 340-8.
18. Fandella A., Scattoni V., Galosi A. et al. Italian prostate biopsies group: 2016 updated guidelines insights // Anticancer. Res. 2017; 37: 413-24.
19. Giesel F.L., Sterzing F., Schlemmer H.P. et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2016; 43: 1400-6.
20. Grubmüller B., Baum R.P., Capasso E. et al. 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies // Cancer Biother. Radiopharm. 2016; 31: 277-86.
21. Haffner M.C., Laimer J., Chaux A. et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity // Mod. Pathol. 2012; 25: 1079-85.
22. Hoilund-Carlsen P.F., Poulsen M.H., Petersen H. et al. FDG in urologic malignancies // PET Clin. 2014; 9: 457-68.
23. Hövels A.M., Heesakkers R.A., Adang E.M. et al., Hoogeveen Y.L. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis // Clin. Radiol. 2008; 63: 387-95.
24. Jadvar H. Is there use for FDG-PET in prostate cancer? // Semin. Nucl. Med. 2016; 46: 502-6.
25. Karanika S., Karantanos T., Li L. et al. DNA damage response and prostate cancer: Defects, regulation and therapeutic implications // Oncogene. 2015; 34: 2815-22.
26. Kitson S.L., Cuccurullo V., Moody T.S. et al. Radionuclide antibody-conjugates, a targeted therapy towards cancer // Curr. Radiopharm. 2013; 6: 57-71.
27. Kratochwil C., Giesel F.L., Stefanova M. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617 // J. Nucl. Med. 2016; 57: 1170-6.
28. Lindenberg L., Ahlman M., Turkbey B. et al. Advancement of MR and PET/MR in prostate cancer // Semin. Nucl. Med. 2016; 46: 536-43.
29. Mansi L., Ciarmiello A., Cuccurullo V. PET/MRI and the revolution of the third eye // Eur. J. Nucl. Med. Mol. Imaging. 2012; 39: 1519-24.
30. Mansi L., Cuccurullo V., Evangelista L. Is radiocholine PET/CT already clinically useful in patients with prostate cancer? // J. Nucl. Med. 2014; 55: 1401-3.
31. Manyak M.J. Indium-111 capromab pendetide in the management of recurrent prostate cancer // Expert Rev. Anticancer Ther. 2008; 8: 175-81.
32. Maurer M.H., Härmä K.H., Thoeny H. Diffusion-weighted genitourinary imaging // Radiol. Clin. North Am. 2017; 55: 393-411.
33. Maurer T., Schwamborn K., Schottelius M. et al. PSMA theranostics using PET and subsequent radioguided surgery in recurrent prostate cancer // Clin. Genitourin. Cancer. 2016; 14: e549-52.
34. Maurer T., Weirich G., Schottelius M. et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer // Eur. Urol. 2015; 68: 530-4.
35. Mease R.C. Radionuclide based imaging of prostate cancer // Curr. Top. Med. Chem. 2010; 10: 1600-16.
36. Mertens K., Slaets D., Lambert B. et al. PET with (18) F-labelled choline-based tracers for tumour imaging: A review of the literature // Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 2188-93.
37. Rahbar K., Schmidt M., Heinzel A. et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis // J. Nucl. Med. 2016; 57: 1334-8.
38. Robu S., Schottelius M., Eiber M. et al. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer // J. Nucl. Med. 2017; 58: 235-242.
39. Rowe S.P., Gorin M.A., Allaf M.E. et al. PET imaging of prostate-specific membrane antigen in prostate cancer: Current state of the art and future challenges // Prostate Cancer Prostatic Dis. 2016; 19: 223-30.
40. Rowe S.P., Macura K.J., Ciarallo A. et al. Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naive and castration-resistant metastatic prostate cancer // J. Nucl. Med. 2016; 57: 46-53.
41. Santoni M., Scarpelli M., Mazzucchelli R. et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: Morphologic and molecular backgrounds and future promises // J. Biol. Regul. Homeost. Agents. 2014; 28: 555-63.
42. Shaish H., Taneja S.S., Rosenkrantz A.B. Prostate MR imaging: An update // Radiol. Clin. North. Am. 2017; 55: 303-20.
43. Silver D.A., Pellicer I., Fair W.R. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues // Clin. Cancer Res. 1997; 3: 81-5.
44. Su H.C., Zhu Y., Ling G.W. et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse // Asian J. Androl. 2017; 19: 267-71.
45. Umbricht C.A., Benešová M., Schmid R.M. et al. 44Sc‑PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 // EJNMMI Res. 2017; 7: 9.
46. Van Leeuwen P.J., Stricker P., Hruby G. et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment // BJU Int. 2016; 117: 732-9.
47. Von Eyben F.E., Kairemo K. Acquisition with (11) C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: A systematic review and meta-analysis // Ann. Nucl. Med. 2016; 30: 385-92.
48. Yu C.Y., Desai B., Ji L. et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: A critical analysis of literature // Am. J. Nucl. Med. Mol. Imaging. 2014; 4: 580-601.
49. Zang S., Shao G., Cui C. et al. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients // Oncotarget. 2017; 8: 12247-58.